Previous close | 0.2420 |
Open | 0.2400 |
Bid | 0.2394 x 700 |
Ask | 0.2451 x 700 |
Day's range | 0.2320 - 0.2450 |
52-week range | 0.2110 - 25.0000 |
Volume | |
Avg. volume | 2,820,387 |
Market cap | 18.088M |
Beta (5Y monthly) | 2.20 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0300 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Composition of matter patent approval underscores the Company’s solid-form technology to maximize future value and ability to strengthen and broaden its intellectual property portfolioSAN DIEGO and LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the approval of a composition of matter patent application by IP Australia, achieving successful examination of a patent on its lead asset, an
SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (the “Company” or “Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures th
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ: SQFT; SQFTP; SQFTW) (“Presidio” or the “Company”), an internally managed, diversified real estate investment trust (“REIT”), has announced that Conduit Pharmaceuticals Inc. (NASDAQ: CDT, CDTTW) (“Conduit”), of which the Company owns approximately 6.3%, is expected to be added to the Russell 2000 Index effective at the open of US equity markets on Monday, July 1, 2024, as part of the annual reconstitution of the Ru